The Impact of Pharmacogenomics on Postoperative Nausea and Vomiting
Open Access
- 1 March 2005
- journal article
- laboratory investigations
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 102 (3) , 543-549
- https://doi.org/10.1097/00000542-200503000-00011
Abstract
Background: Some patients treated with ondansetron for postoperative nausea and vomiting do not respond to therapy. One possible mechanism for this failure is ultrarapid drug metabolism via the cytochrome P-450 system, specifically the enzyme 2D6 (CYP2D6). Ultrarapid metabolism is seen in patients with multiple functional copies (>/= 3) of the CYP2D6 allele. This study was designed to determine whether patients who were given prophylactic ondansetron and had multiple CYP2D6 alleles had an increased rate of postoperative nausea and vomiting. Methods: Two hundred fifty female patients undergoing standardized general anesthesia were given 4 mg ondansetron 30 min before extubation. Patients were observed for symptoms of nausea and vomiting. DNA was extracted from blood in all patients and was analyzed by using a gene-specific probe to determine the CYP2D6 gene copy number and genotyped by polymerase chain reaction amplification with a custom oligonucleotide microarray to determine the specific CYP2D6 genotypes. Results: Eighty-eight patients experienced nausea, and 37 of those patients also had vomiting. In patients with one, two, or three CYP2D6 copies, the incidences of vomiting were 3 in 33 (27%), 27 in 198 (14%), and 7 in 23 (30%), respectively. The incidence of vomiting in subjects with three CYP2D6 copies was significantly different from those with two copies, but not from those with one copy. When analyzed by genotype, the incidences of vomiting in poor, intermediate, extensive, and ultrarapid metabolizers were 1 in 12 (8%), 5 in 30 (17%), 26 in 176 (15%), and 5 in 11 (45%), respectively (P < 0.01 vs. all other groups). There were no differences between groups in the incidence of nausea based on CYP2D6 copy number or genotype. Conclusions: Patients with three copies of the CYP2D6 gene, a genotype consistent with ultrarapid metabolism, or both have an increased incidence of ondansetron failure for the prevention of postoperative vomiting but not nausea.Keywords
This publication has 16 references indexed in Scilit:
- A Randomized Comparison of a Multimodal Management Strategy Versus Combination Antiemetics for the Prevention of Postoperative Nausea and VomitingAnesthesia & Analgesia, 2004
- Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonistsPharmacogenetics, 2004
- A risk adapted approach reduces the overall institutional incidence of postoperative nausea and vomitingCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2004
- Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 GenotypesJournal of Clinical Oncology, 2002
- Genetic susceptibility to adverse effects of drugs and environmental toxicants: The role of the CYP family of enzymesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
- Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trialJournal of Clinical Anesthesia, 1999
- Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomitingBritish Journal of Anaesthesia, 1996
- Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.British Journal of Clinical Pharmacology, 1994
- Postoperative Nausea and VomitingAnesthesiology, 1992
- EditorialAnesthesia & Analgesia, 1991